Navigation Links
Thomson Reuters Cortellis Drives Drug Discovery and Development With Powerful New Web Services
Date:2/28/2012

PHILADELPHIA, and LONDON, Feb. 28, 2012 /PRNewswire/ -- Thomson Reuters announced the availability of Cortellis for Informatics, a new capability that speeds access to critical life sciences research and development information found on its premiere life sciences platform, Thomson Reuters Cortellis.

Cortellis for Informatics uses sophisticated application programming interfaces (APIs) to enhance the research and development process by delivering real-time access to powerful information and tools for biopharmaceutical competitive intelligence, drug pipeline, and drug research and development.

Each API integrates Thomson Reuters data with proprietary content and public information sources into a comprehensive view that is customized to meet the needs of a company, team or individual researcher. With Cortellis for Informatics, data can be shared in a number of ways, including dashboards, custom reports and alerts, and intranet and mobile applications.

"We worked closely with Thomson Reuters during their development and testing phases, and I am delighted to say that the Cortellis APIs exceed my expectations and allow us to take advantage of Thomson Reuters content in the systems that drive our business," said Dr. William Hayes, director of Decision Support at Biogen Idec.

"For life sciences professionals, Cortellis for Informatics is a significant step forward," said Wendy Hamilton, senior vice president at Thomson Reuters. "The advanced options for obtaining information give customers access to our content beyond Cortellis' highly intuitive web portal. Information can now be incorporated directly on the user's preferred systems, customized to their needs, creating additional opportunities for integration across the entire organization."

Cortellis for Informatics streamlines information sharing across all levels of the organization. Instead of using multiple systems to manage workflows, researchers access up-to-the-minute news in the office, in meetings or at the bench. This ability to deploy high-quality Thomson Reuters information across the whole company in real time within internal systems provides greater opportunities for collaboration in the scientific search and discovery process.

Cortellis for Informatics provides web services for investigational drugs, drug targets, ontologies, patents, clinical trials and analytics.

For more information on Cortellis, visit cortellis.thomsonreuters.com.

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals.  We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 55,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
2. Despite Decline in Share of Global Output, U.S. Science Impact Still Strong, Says Thomson Reuters
3. Thomson Reuters Names Hottest Researchers and Papers of 2007-2008
4. APS Healthcare and Thomson Reuters to Manage New York States Medicaid Clinical Best Practices Review Program
5. Thomson Reuters Commemorates World IP Week with Series of Strategic Intellectual Property Seminars Across the U.S.
6. Thomson Reuters Examines Highly Cited Research in Bioterrorism
7. Thomson Reuters Makes Disease Briefing on Influenza Covering H1N1 (Swine Flu) Publicly Available
8. Brazils Scientific Research On The Rise, Thomson Reuters Study Finds
9. Thomson Reuters Partners With Sagient Research
10. Thomson Reuters Announces 2009 Edition of the CMR International Pharmaceutical R&D Factbook
11. Thomson Reuters Joins the InChI Trust
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading provider ... nationwide oncology Clinical Nurse Educator (CNE) network, which will launch ... for communication among health care professionals to enhance the patient ... office staff, and other health care professionals to help women ... cancer. ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking events company, ... today. The bold new look is part of a transformation to increase awareness, ... significant growth period. , It will also expand its service offering from its signature ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting in ... professor in Harvard University’s Departments of Physics and Astronomy, has been selected for membership ... the winning team for the 2015 Breakthrough Prize in Fundamental physics for the discovery ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):